A Single-center, Un-controlled, Open-labeled Trial of the Long-term Safety of Lamazym Aftercare Treatment of Subjects With Alpha-Mannosidosis Whom Previously Participated in Lamazym Trials
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 22 Apr 2017
At a glance
- Drugs Velmanase alfa (Primary)
- Indications Alpha-Mannosidosis
- Focus Adverse reactions
- Sponsors Chiesi Farmaceutici SpA; Zymenex A/S
- 01 Sep 2016 Planned End Date changed from 1 Feb 2017 to 1 Dec 2018.
- 01 Sep 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
- 09 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.